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Abstract
Background: MicroRNAs (miRNAs) are small regulatory RNAs that are implicated in cancer pathogenesis and have recently
shown promise as blood-based biomarkers for cancer detection. Epithelial ovarian cancer is a deadly disease for which
improved outcomes could be achieved by successful early detection and enhanced understanding of molecular
pathogenesis that leads to improved therapies. A critical step toward these goals is to establish a comprehensive view of
miRNAs expressed in epithelial ovarian cancer tissues as well as in normal ovarian surface epithelial cells.
Methodology: We used massively parallel pyrosequencing (i.e., ‘‘454 sequencing’’) to discover and characterize novel and
known miRNAs expressed in primary cultures of normal human ovarian surface epithelium (HOSE) and in tissue from three
of the most common histotypes of ovarian cancer. Deep sequencing of small RNA cDNA libraries derived from normal HOSE
and ovarian cancer samples yielded a total of 738,710 high-quality sequence reads, generating comprehensive digital
profiles of miRNA expression. Expression profiles for 498 previously annotated miRNAs were delineated and we discovered
six novel miRNAs and 39 candidate miRNAs. A set of 124 miRNAs was differentially expressed in normal versus cancer
samples and 38 miRNAs were differentially expressed across histologic subtypes of ovarian cancer. Taqman qRT-PCR
performed on a subset of miRNAs confirmed results of the sequencing-based study.
Conclusions: This report expands the body of miRNAs known to be expressed in epithelial ovarian cancer and provides a
useful resource for future studies of the role of miRNAs in the pathogenesis and early detection of ovarian cancer.
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Introduction
Epithelial ovarian cancer is the leading cause of gynecologic
cancer-related deaths in the United States [1], with late-stage
diagnoses having a ,30% five-year survival rate [2]. Survival rates
could be improved by a better understanding of molecular
pathogenesis, which may lead to development of superior targeted
therapies, as well as by earlier detection of disease at a surgically
curable stage. When detected at a stage in which disease is
confined to the ovary, for example, the five-year survival rate
increases to .80%. Clinically effective biomarkers for early
detection of ovarian cancer could substantially improve survival
rates and ovarian cancer biomarker discovery is an important area
of ongoing research [3].
MicroRNAs (miRNAs) are a class of small (,22 nt) non-coding
RNA molecules that act post-transcriptionally to regulate gene
expression [4]. MicroRNAs originate from hairpin RNA precur-
sors that are processed to generate both the functional mature
miRNA and a miRNA ‘‘star form’’ of similar length derived from
the opposite strand of the hairpin. MicroRNA-mediated modu-
lation of biological systems has been found to be perturbed in
multiple diseases [5], including cancer [6–8]. Expression patterns
of miRNAs correlate with tissue of origin [8,9], prognosis [10,11]
and with clinical cancer behaviors [12], making miRNAs valuable
tissue-based biomarkers. Furthermore, we and others have
recently shown that tumor-derived miRNAs enter the bloodstream
at measurable levels, indicating that miRNAs released by tumor
tissue represent a powerful new class of blood-based, minimally
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a strong impetus for a comprehensive analysis of the miRNA
repertoire expressed in epithelial ovarian cancer.
Several recent reports have begun to characterize miRNA
expression in ovarian cancer using microarrays spotted with
probes for a varying number of known miRNAs [17–20].
Although these are pioneering studies, they also have limitations.
The foremost of these is that all arrays reported to date have
incomplete coverage of known miRNAs. Of the 959 miRNAs and
star forms present in miRBase (release 12.0) [21,22], most
microarray platforms applied to date assay only a few hundred
miRNAs, with the most comprehensive of the arrays assaying 470
miRNAs and star forms. In addition, microarray approaches only
measure previously identified miRNAs and are not equipped to
discover and profile novel miRNAs. This is an important
distinction to make given that several reports suggest that a
significant number of miRNAs, particularly those that may be cell-
type specific in expression, remain to be discovered [23,24].
Finally, because of the small size of miRNAs and the challenges of
achieving uniform hybridization conditions across an entire
miRNA microarray, there is potential for cross-hybridization of
miRNAs that are highly related in sequence, making it sometimes
impossible to definitively distinguish between miRNAs differing by
one or two nucleotides.
To overcome the limitations associated with microarray studies,
we used ‘‘next generation’’ sequencing technology (specifically
massively parallel pyrosequencing using the 454 Life Sciences
platform) of small RNA cDNA libraries to more comprehensively
characterize miRNA expression in epithelial ovarian cancer, as
well as in primary cultures of normal ovarian surface epithelial
cells. This approach, which is based on 59 and 39 universal linker
ligation/RT-PCR and counting of sequence reads obtained for
distinct miRNAs, can in theory capture all miRNAs present in the
RNA samples (including ones of novel sequence) and permits
precise identification of miRNAs, even when differing by only a
single nucleotide. We generated a total of 738,710 sequence reads
from four small RNA cDNA libraries representing normal primary
human ovarian surface epithelium (HOSE) cultures and three
common epithelial ovarian cancer subtypes (serous, clear cell and
endometrioid). Here we describe the results of this effort, including
the identification and profiling of both previously annotated and
novel miRNAs expressed in ovarian cancer.
Methods
Additional details regarding cell culture, RNA isolation, small
RNA cDNA library construction, massively parallel sequencing,
computational pipeline description and miRNA TaqMan quan-
titative reverse-transcription polymerase chain reaction (qRT-
PCR) are provided in detail in Supplementary Methods S1
and in [23].
Cell culture and clinical materials
Normal primary human ovarian surface epithelial (HOSE) cells
were obtained from the normal ovaries of postmenopausal women
using a modification of the technique described previously in [25].
In all cases, specimens were taken from normal-appearing ovarian
surface epithelium, which was confirmed following histopatholog-
ical review. HOSE specimens were obtained under a protocol that
was approved by the Research Review Committee and Internal
Review Board at the Fox Chase Cancer Center from patients
undergoing clinically indicated surgery (either prophylactic risk
reduction salpingo-oophorectomy or total abdominal hysterecto-
my with bilateral salpingo-oopherectomy) and who provided
written informed consent for tissue not required for diagnosis to be
used for research. Primary HOSE cells were cultured using media
described in [26] at 37uCi n5 %C O 2.
Ovarian cancer snap-frozen specimens corresponding to Stage
III/IV epithelial ovarian cancer (19 serous, four clear cell and 10
endometrioid) contained .70% malignant epithelial cellularity as
assessed by pathologist review of an adjacent stained tissue section.
Ovarian cancer specimens were obtained from the Pacific Ovarian
Cancer Research Consortium Repository. Specimens were
collected under a protocol approved by the Fred Hutchinson
Cancer Research Center Institutional Review Board and were
obtained from patients who had provided written informed
consent for tissue not required for clinical management purposes
to be used for research.
RNA extraction and miRNA library preparation
Normal primary HOSE cultures (passage 4–7) were lysed in
600 ml mirVana Lysis/Binding buffer (Ambion, Inc., Austin, TX).
Tumor specimens (,100 mg each) were homogenized in a Qiagen
Tissuelyser with 600 ml mirVana Lysis/Binding buffer. Total
RNA was extracted from both sample types using the mirVana
TM
miRNA isolation kit (Ambion) per the manufacturer’s protocol.
RNA from snap-frozen tumors (19 serous, four clear cell and 10
endometrioid tumors, respectively) was pooled according to
histologic subtype. MicroRNA cloning was performed as previ-
ously described [27], (http://web.wi.mit.edu/bartel/pub/protocols/
miRNACloningUpdate0705.pdf) with modifications at the amplifi-
cation steps to prepare the samples for massively parallel sequencing
by 454 Life Sciences.
Custom bioinformatic data analysis pipeline
Processing and annotation of sequences based on identity to
known transcribed RNAs or as novel miRNAs was performed
using a custom bioinformatics pipeline described in detail in
Supplementary Methods S1.
Measurement of miRNA levels in RNA from clinical
samples using TaqManH qRT-PCR assays
Total RNA was reverse transcribed and prepared for qRT-PCR
using the TaqManH miRNA Reverse Transcription Kit and
miRNA-specific stem-loop primers (Applied BioSystems, Inc.) as
previously described [23]. Data was analyzed with SDS Relative
Quantification Software version 2.2.2 (Applied BioSystems, Inc.),
with the automatic Ct setting for assigning baseline and threshold
for Ct determination.
Results
Overview of small RNA cDNA libraries and 454
sequencing
Small RNA cDNA libraries were constructed from RNA sample
pools isolated from primary cultures of histologically normal
primary HOSE (n=4) and epithelial ovarian cancer specimens of
serous (OSC, n=19), clear cell (OCC, n=4) and endometrioid
(OEC, n=10) histologies. Tumor specimens were selected to
contain at least 70% malignant epithelial cells. Total RNA was
size-fractionated via polyacrylamide gel electrophoresis and small
RNAs corresponding in molecular weight to the mature miRNA
population (18–24 nt fraction) were gel extracted and processed
for reverse transcription and PCR amplification to create cDNA
libraries (Figure 1A). Massively parallel pyrosequencing using the
454 Life Sciences’ platform generated 80,501 normal HOSE
reads, 273,739 OSC reads, 292,942 OCC reads, and 91,528 OEC
Ovarian Cancer microRNAs
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OSC, 37,792 OCC and 13,134 OEC non-redundant sequences.
The greater number of reads corresponding to serous and clear
cell samples was due to greater depth of sequencing (i.e., a larger
portion of the sequencing plate used) rather than to any particular
variations during library preparation.
Sequence data was processed using our custom computational
pipeline (Figures 1B, S1 and Table S1). The initial steps of the
pipeline identified sequence matches to databases of previously
annotated RNAs (e.g., known miRNAs, other noncoding RNAs,
messenger RNAs) and to highly repetitive sequence elements.
Remaining sequences were processed to identify novel miRNAs
(Figure S1; details of the computational pipeline are provided in
Supplementary Methods S1). In the next sections, we discuss
in detail the sequences matching to known miRNAs and the
identification of novel miRNAs.
MicroRNA profiling: previously annotated miRNAs.
Matches to known miRNAs in miRBase (release 12.0) [21,22]
represented 68–73% of the reads, depending on the dataset
(Figure 1B and Table S1) and corresponded to a total of 498
known miRNAs (including star forms). The cloning frequency of
individual miRNAs, expressed as a fraction of total reads obtained
from a given sample, can be used to compare relative expression of
miRNAs between samples [28–30]. The global summary of our
454 sequencing datasets is presented in Figure 2, which depicts
the relative expression of miRNAs between normal primary
HOSE and cancer tissue datasets (A), as well as between the three
epithelial ovarian subtypes (B). The most differentially expressed
miRNAs (i.e., $4 fold-change) are shown as red dots. It is notable,
though not unexpected, that the ovarian cancer histologic subtype
miRNA profiles were more different from normal HOSE (A) than
they were from each other (B). Tabulated 454 sequencing data for
miRNA abundance in all datasets, as well as miRNA names and
abundance ratios for all pairwise comparisons between sample
types, are provided in their entirety in Table S2.
The overlap of differentially expressed miRNAs between
subtypes is visualized in the Venn diagrams in Figure 3, which
also incorporate miRNAs excluded from Figure 2 because of zero
reads in either normal HOSE or ovarian cancer samples. From
the intersection of the three groups in the Venn diagrams, it is
evident that in many cases miRNAs differentially expressed in
ovarian cancer relative to normal HOSE show the same pattern of
differential expression regardless of histologic subtype. Table S3
provides a full list of names of individual miRNAs and expression
ratio and P-values for the comparisons summarized in Figure 3.
We directly compared miRNA expression between ovarian
cancer histologic subtypes by deriving expression ratios for each
miRNA based on fractional abundance values. Significance was
assessed using Fisher’s exact test. The top ten miRNAs
differentially expressed in each of the pairwise comparisons of
Figure 1. Small RNA cDNA library generation and data analysis pipeline. A. Small RNAs were isolated from normal primary HOSE cultures
and from serous (OSC), clear cell (OCC) and endometrioid (OEC) ovarian cancer tissues. Following 59 and 39 linker ligation, RT-PCR was performed to
generate four independent cDNA libraries of small RNAs that were then used as templates for massively parallel pyrosequencing (454 sequencing). B.
Description of the steps in the data analysis pipeline. The initial step of the data analysis was removal of sequences corresponding to 18 nt
and 24 nt RNA markers that had been spiked into the total RNA prior to gel electrophoresis. Percentage of total reads from HOSE, OSC, OCC and OEC
datasets classified into the designated categories and filtered out at each step are listed in the table on the right. At the bottom of the table, the
number of ‘‘unique sequences’’ represents the non-redundant sequences derived after collapsing multiple reads of identical sequence. Some
canonical sequences map to more than one locus in the genome. At completion of the analysis, 199 sequences totaling 215 reads and mapping to
568 loci met our criteria for canonical hairpin-derived sequences from the combined datasets.
doi:10.1371/journal.pone.0005311.g001
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for all miRNAs are provided in their entirety in Table S2).
Among the most histologic subtype-specific miRNAs are miR-
449a (serous-specific), miR-499-5p/miR-375/miR196a/miR-
196b/miR-182 (endometrioid-specific) and miR-486-5p/miR-
144/miR-30a/miR-199a-5p (clear cell-specific).
Validation of 454 sequencing miRNA expression results
by qRT-PCR. We used commercially available miRNA
TaqMan qRT-PCR assays as an independent confirmation of
miRNA differential expression identified by 454 sequencing.
MicroRNA TaqMan qRT-PCR assays were performed for a
sample of 38 known miRNAs that were selected based on over- or
under-expression with respect to primary normal HOSE, or based
on differential expression between different subtypes of ovarian
cancer (calculated based on 454 sequencing data). Taqman assays
were carried out on aliquots of the same RNA pools used for
sequencing. Thirty-six of the 38 differentially expressed miRNAs
examined by TaqMan qRT-PCR demonstrated consistent results
with those obtained by 454 sequencing (Figures 4 and 5, A, B,
C). Of the eight miRNAs identified by 454 sequencing to be over-
expressed in ovarian cancer relative to the normal HOSE group
(Figure 4A), all eight demonstrated over-expression in serous and
clear cell cancer subtypes when measured using TaqMan qRT-
PCR, while six of the eight showed consistent results in the
endometrioid cancer subtype (miRs-126*,-142-3p, 195, 200a,
200b, 200c, 338-3p, 378*). Nine miRNAs were under-
expressed in ovarian cancer relative to normal HOSE
(Figure 4B), with all subtypes showing consistent results when
measured by TaqMan qRT-PCR. There were six miRNAs that
were undetectable (zero reads) in normal HOSE cultures
(Figure 4C), but had detectable expression in OEC, OSC and/
or OCC in the 454 sequencing data, and they likewise showed
increased expression in ovarian histologic subtype samples versus
normal primary HOSE when examined by TaqMan qRT-PCR
(Figure 4C).
Fifteen miRNAs identified by 454 sequencing to be differentially
expressed across ovarian cancer subtypes (Figure 5A, B, C)
showed similar expression patterns when quantitated by qRT-
PCR. Eight miRNAs were over-expressed specifically in endome-
trioid ovarian cancer (Figure 5A), four in serous cancer
(Figure 5B), and three in clear cell cancer (Figure 5C) relative
to the other subtypes.
Analysis of sequencing data to identify novel hairpin-
derived small RNAs. Having validated 454 sequencing results
corresponding to differential expression of previously annotated
miRNAs, we next turned to the identification of novel miRNA
Figure 2. Comparison of abundance of known miRNAs across datasets. Datasets are compared pairwise, plotting the log of the fraction of
total reads for a given miRNA in a given dataset against its corresponding value in the second dataset. For each plot, only miRNAs that were
sequenced in both datasets are plotted; miRNAs that were sequenced only in one of the two datasets are not shown. The top row (A), compares
ovarian cancer datasets (OSC, OCC and OEC) to normal primary HOSE cultures; the bottom row (B), compares ovarian tumor histologic subtypes to
each other. Red dots signify miRNAs that had a fold change $4.
doi:10.1371/journal.pone.0005311.g002
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features including messenger RNAs, tRNAs and other known
noncoding RNAs, the remaining sequences were aligned to the
reference human genome sequence (NCBI Build 36.1) [31].
Sequences were required to match the human genome sequence
perfectly to be carried further for additional computational analysis,
with the only exception to this being sequences that demonstrated
additionof 1–3 non-templated nucleotidesat the 39terminus.In these
cases, we trimmed non-templated bases from the original sequence
and it was then carried further for analysis [32,33].
The data processing steps described thus far yielded 841 normal
HOSE, 2,840 OSC, 11,224 OCC, and 1,764 OEC unique
sequences corresponding to novel small RNAs. These unique
sequences corresponded to 1,766 normal HOSE, 5,795 OSC,
19,464 OCC and 3,301 OEC genomic loci that could potentially
generate these small RNAs (Figure 1B, Table S1). The data
analysis pipeline next screened these genomic loci (in addition to
100 nucleotides of up- and down-stream flanking sequence) for the
presence of a predicted hairpin secondary structure by computing
free energy, shape probability (as determined by the RNAshapes
program [34]) and the Randfold-computed [35] P-value of
predicted secondary structures. A detailed description of hairpin
folding criteria is provided in Supplementary Methods S1 and
in [23]. This resulted in 224 normal HOSE, 511 OSC, 500 OCC,
and 247 OEC novel small RNAs found to be potentially derived
from a precursor hairpin structure.
Sequences passing the above filtering criteria from the four
datasets were then combined and sorted with respect to
chromosomal coordinates into groups sharing 59 ends. From each
of these groups we chose a ‘‘canonical’’ sequence representing that
genomic locus. The canonical sequences were chosen based on a
common 59 terminus, abundance, and sequence length as
described previously [23] (additional details are provided in
Supplementary Methods S1). This process further refined the
data into a combined list of 199 unique sequences (potentially
derived from 568 genomic loci) that we designated as ‘‘novel
hairpin-derived small RNAs’’ from which we identified novel and
candidate miRNAs.
Identifying novel and candidate miRNAs. In order to
determine which sequences to designate as novel miRNAs, we
screened the set of novel hairpin-derived small RNAs using criteria
similar to those used in other recent miRNA discovery studies
Figure 3. Differential expression of miRNAs in ovarian tumor histologic subtypes relative to normal primary HOSE. Venn diagrams
depict numbers of miRNAs differentially expressed in ovarian cancer histologic subtypes relative to normal primary human ovarian surface epithelium
(HOSE) cultures. Criteria for a miRNA as differentially expressed was defined by a fold-change $4 with a Fisher’s exact test P-value,5.0610
26 for
miRNAs that had detectable expression in both HOSE and ovarian cancer samples, or by a Fisher’s exact test P-value,5.0610
26 alone in cases where
a fold-change value was indefinable due to zero reads for a given miRNA in either the HOSE or ovarian cancer comparison sample. A total of 74 over-
expressed miRNAs (Panel A) and 49 under-expressed miRNAs (Panel B) in ovarian cancer with respect to normal HOSE were identified. MicroRNAs that
were found to be consistently over-expressed or consistently under-expressed in all three ovarian cancer histologic subtypes are listed by name.
doi:10.1371/journal.pone.0005311.g003
Ovarian Cancer microRNAs
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of multiple reads sharing the same 59 terminus, iii. absence of
annotation indicating non-miRNA biogenesis, iv. shared seed
region with a known animal miRNA and v. presence of
corresponding miRNA star form read(s). We considered
including phylogenetic sequence conservation as a criterion;
however, this did not add significantly to our analysis as none of
the novel hairpin-derived miRNAs were conserved beyond
Figure 4. Validation of 454 sequencing-derived miRNA expression results by qRT-PCR: miRNAs differentially expressed in ovarian
cancer relative to normal HOSE. The graphs display miRNA Taqman qRT-PCR results for a sampling of miRNAs identified by 454 sequencing to be
over-expressed (Panel A) or under-expressed (Panel B) in ovarian cancer relative to normal HOSE. Relative expression values derived from 454
sequencing are displayed on the left segment of each graph for comparison. Relative expression values of miRNAs in endometrioid (OEC, black bars),
serous (OSC, white bars) and clear cell (OCC, grey bars) cancers are depicted. MicroRNAs that were not detected in normal HOSE by 454 sequencing
but were detected in ovarian cancer are presented in Panel C, where miRNAs are ordered by descending expression (which corresponds to ascending
cycle threshold, Ct) in normal HOSE. 454 sequencing data is given in terms of percentage of total reads within each sample. UD, undetectable by
miRNA TaqMan qRT-PCR.
doi:10.1371/journal.pone.0005311.g004
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conserved microRNAs are likely to have already been discovered
using computational approaches followed up by directed
validation experiments.
Using the criteria above, we identified six novel miRNAs. All of
the six met criteria i–iii and three of the six met criterion iv and
three met criterion v (Figure 6; more detail is provided in Table
S5). In addition, mapping the novel miRNA sequences to the
reference human genome sequence revealed that three of the six
novel miRNAs are present in introns of other genes (and encoded
on the same strand as the respective host genes) (Figure 6), much
like many previously annotated miRNAs [37,38]. Two of our
novel miRNAs are located in annotated repeats, but have strong
enough supporting evidence that they were designated as novel.
The context of the predicted precursor structure and the sequence
of miRNA star forms corresponding to novel miRNAs is given in
Figure 6.
The remaining sequences comprised 181 hairpin-derived small
RNAs (corresponding to 550 genomic loci). We sought to select
from this list the most promising sequences to designate as
‘‘candidate miRNAs’’ that might be confirmed in the future as bona
fide miRNAs as additional evidence accumulates. Candidate
miRNAs were required to meet criteria i–iii and have some
additional form of supporting evidence (i.e., shared seed region
with a known miRNA). This allowed us to refine a final list of 39
candidate miRNAs (potentially originating from 50 genomic loci)
(Table S5).
Discussion
The work reported here was motivated by the hypothesis that
the entire repertoire of miRNAs expressed in ovarian cancer,
including potentially tissue- and cancer-specific miRNAs, had not
yet been elucidated. The massively parallel sequencing approach
allowed us to be comprehensive (i.e., identifying not only known
but also novel miRNAs), and the ‘‘digital’’ nature of the data
permitted a semi-quantitative estimation of the relative expression
level for many miRNAs. Using this approach, we discovered six
novel and 39 candidate miRNAs, and delineated the expression
pattern of 498 previously annotated miRNAs in normal primary
HOSE cultures and epithelial ovarian cancer tissues. It is notable
that of the four published miRNA microarray studies of ovarian
Figure 5. Validation of 454 sequencing-derived miRNA expression results by qRT-PCR: miRNAs differentially expressed between
ovarian cancer histologic subtypes. The graphs display Taqman qRT-PCR results for miRNAs differentially expressed between ovarian cancer
subtypes, with 454 sequencing-derived data presented for comparison in the left segment of each graph. Relative expression values of miRNAs
specifically over-expressed in endometrioid (Panel A, OEC, black bars), serous (Panel B, OSC, white bars) and clear cell (Panel C, OCC, grey bars) cancers
are depicted. UD, undetectable by miRNA TaqMan qRT-PCR.
doi:10.1371/journal.pone.0005311.g005
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platforms was limited to 470 human miRNAs and star forms
[17], while the current release of miRBase (release 12.0) [21,22]
contains 969 human miRNAs and star forms. Furthermore, 223 of
the known miRNAs we identified and characterized in our
sequencing datasets were not represented on even the most
comprehensive microarray. Therefore, the results presented here
substantially extend the breadth of knowledge of miRNAs
expressed in ovarian cancer.
The identification of novel miRNAs in our data is particularly
notable. Given that these novel miRNAs have not been detected in
multiple large-scale miRNA sequencing studies of other tissues, we
speculate that they are expressed in an ovarian cancer-specific
manner and may be of special interest as cancer biomarkers.
Future studies will be needed to test this hypothesis, as well as to
investigate the biological roles of these novel miRNAs in ovarian
cancer pathogenesis.
Taken together, the known and novel miRNAs identified in this
study provide a pool of candidate miRNA markers for future
analysis as blood-based markers for the detection of ovarian
cancer. Differential expression between normal and malignant
states may provide one method for prioritization of candidates
moving forward. We also envision that the miRNAs that we found
to be differentially expressed between histologic cancer subtypes
could serve a dual purpose as blood-based markers for both cancer
detection and histologic classification.
One of the unique features of our study is the use of primary
cultures of normal human ovarian surface epithelium as the
normal comparison group. Although the ovarian surface epithe-
lium (along with nearby distal fallopian tube epithelium) is
considered the origin of epithelial ovarian cancer [39] most other
miRNA profiling studies have typically used whole ovary as the
normal comparison. This is problematic for identifying miRNAs
that are differentially expressed in ovarian cancer relative to
normal because the single cell-thick surface epithelial layer
comprises far less than 1% of the cellular content of the whole
ovary. Performing comparisons of ovarian cancer tissue to an
appropriate normal control is a challenging problem in ovarian
cancer research. Our approach, although it avoids the problems
associated with using whole ovary as a normal sample, has the
limitation that we do not know whether and which changes in
microRNA expression may be attributed to culture conditions
used for primary HOSE cell culture. Future studies incorporating
parallel analyses of primary cell cultures derived from ovarian
cancer tissues may address this question.
Although the use of different types of ‘‘normal’’ ovarian
specimens makes comparison of our data with other studies
difficult in most cases, in one microarray study, however, the
normal control was human ovarian surface epithelial cells that had
been immortalized using a retrovirus expressing human papillo-
mavirus-derived viral oncoproteins E6 and E7 [17,40]. Because
the normal primary HOSE cultures we studied are not
immortalized, comparison of our results to that report could
identify miRNAs that may be induced by immortalization by E6
and E7 proteins. A notable finding from this comparison is that
whereas we identified the miR-200 family of miRNAs (miR-200a/
b/c, miR-141 and miR-429) to be expressed at low levels in
normal HOSE with highly increased expression in ovarian cancer,
the study using E6/E7-immortalized HOSE did not find increased
expression of miR-200 family miRNAs in ovarian cancer. This
family of miRNAs has important functions in repressing the
proteins ZEB1 and ZEB2 [41–46], which are transcription factors
that function to promote epithelial-to-mesenchymal transition
[47–51]. One appealing interpretation of the differing results is
that primary normal HOSE express low levels of the miR-200
family miRNAs, but the E6 and E7 viral oncoproteins induce
miR-200 family expression, which may be an important step in
ovarian carcinogenesis given that this miRNA family was the most
highly over-expressed miRNA family in all ovarian cancer types
we examined. Future work will be needed to address this
hypothesis.
In summary, our work expands the current view of the
repertoire of miRNAs expressed in normal HOSE and common
histologic subtypes of ovarian cancer. Our results represent a
Figure 6. Novel miRNAs discovered by 454 sequencing. Putative secondary structures for the six novel miRNAs discovered in this study are
shown. Novel miRNA sequences are shown in red and star forms of novel miRNAs are shown in blue (if identified in our sequencing data). Sequences
are novel with respect to miRBase release 12.0 [21,22]. Identifiers in parentheses refer to the miRNA star forms where these were identified in the 454
sequencing data. Corresponding details of the novel miRNAs are given in the table below the hairpin structures.
doi:10.1371/journal.pone.0005311.g006
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cancer and of their applications as clinically useful biomarkers.
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus [52] and are accessible
through GEO Series accession number GSE15190 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15190).
Supporting Information
Table S1 Overview of computational pipeline data processing
results. Shaded lines represent steps at which sequences are pruned
out of the dataset before the next step. The left column for each
dataset contains the number of nonredundant unique sequences,
and the right column is the sum of all the reads for each sequence.
Found at: doi:10.1371/journal.pone.0005311.s001 (0.02 MB
XLS)
Table S2 Identity, abundance data and pairwise relative
expression data for all known miRNAs in 454 sequencing datasets.
Columns B-I display the number of reads and fractional
abundance values for miRNAs corresponding to the 4 sample
types studied. Columns J-U provide pairwise comparisons of
expression (along with Fisher’s exact test P-values) of each miRNA
between all combinations of the sample types studied.
Found at: doi:10.1371/journal.pone.0005311.s002 (0.21 MB
XLS)
Table S3 MicroRNAs differentially expressed between ovarian
cancer and normal HOSE.
Found at: doi:10.1371/journal.pone.0005311.s003 (0.05 MB
XLS)
Table S4 MicroRNAs differentially expressed between ovarian
cancer histologic subtypes. Bold blocks of numbers show top 10
most differentially expressed known miRNAs between ovarian
cancer subtypes.
Found at: doi:10.1371/journal.pone.0005311.s004 (0.04 MB
XLS)
Table S5 Novel and candidate miRNAs. Alternating yellow and
orange miRNAs represent 59-39 pairs, with the yellow indicating
the dominant sequence. Pink rows are the two remaining novel
miRNAs. The non-highlighted sequences represent candidate
miRNAs.
Found at: doi:10.1371/journal.pone.0005311.s005 (0.04 MB
XLS)
Methods S1
Found at: doi:10.1371/journal.pone.0005311.s006 (0.12 MB
DOC)
Figure S1 Flow chart of sequence data analysis pipeline. The
flow chart shows the steps in the computational analysis of the 454
sequencing data. At each step, sequences may be removed for
further analysis, or carried on to the next step in the pipeline. The
first steps remove previously annotated features from the pipeline,
and then remaining sequences are tested for presence of hairpin
secondary structure and other criteria to be designated novel
miRNAs. Bolded lower-case letters are referred to in the
Supplementary Methods.
Found at: doi:10.1371/journal.pone.0005311.s007 (0.77 MB TIF)
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